Tirzaglix is a dual GIP and GLP-1 receptor agonist representing the next generation of peptide-based therapies for weight management and metabolic health. Supported by extensive clinical research, it works by enhancing insulin sensitivity, regulating appetite, and improving glucose metabolism, offering a powerful and innovative approach to long-term wellness with a proven safety and efficacy profile.

​

Treatment with tirzepatide is initiated at a low weekly dose (2.5 mg) and gradually increased to improve tolerability and reduce gastrointestinal side effects. Clinical studies have shown that consistent use of tirzepatide can produce substantial weight reduction—often exceeding 20% of body weight—while also delivering significant improvements in glucose control and markers of metabolic health.